Bryan Garnier - TESCO (TSCO) Tesco: P10 UK market share on the same trend as recent months

Report

Bryan Garnier

Clement Genelot

Tesco: P10 UK market share on the same trend as recent months

Following the P10 Kantar market share release, we continue to favour Tesco for its exposure to a still-healthy UK grocery market (no deflation, volume/mix no longer negative, no price war in sight until late 2025) and its robust commercial execution currently unlocking strong market share momentum

09/10/2024 1 EN

Underlying

TESCO

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Clement Genelot

Other Reports on these Companies

Bryan Garnier

Tesco: "beat-and-raise" cycle still in motion post-H1

Post-another strong H1 publication and guidance upgrade, we continue to view Tesco as a "beat-and-raise" story with continued ability to lift guidance and positively surprise, and have lifted our FY 2024-26 FCF by c.6% and our PT to 404p. Tesco's exposure to the still healthy UK market combined wit

October 8, 2024 October 8, 2024 1 EN

Bryan Garnier

Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

Post Tesco's strong set of H1 figures (particularly EBIT while sales were just in line), we view the FY retail EBIT guidance upgrade to "around GBP2.9bn" as sufficient enough to please investors and prompt a few estimates upgrades among sell-side analysts. Tesco's exposure to the healthy UK market

October 3, 2024 October 3, 2024 1 EN

Vicore Pharma: interesting play in the IPF space

On the back of its SEK882m capital increase and the start of a phase 2b trial with its lead asset buloxibutid in IPF, we take the opportunity to refresh our investment case on Vicore Pharma. Going into the phase 2b, we appreciate the diverse multi-modal MoA that buloxibutid presents which are relev

3h / 16m 3h / 16m 1 EN

Loic Morvan ... (+2)

Loic Morvan
Paul Rouviere

Rémy Cointreau: we lower our FY24/25 EBIT as China confirms higher tariffs on cognac

Following yesterday's decision by the Chinese government to impose higher tariffs on cognac in China and ahead of an expected poor Q2 sales release, we cut our FY 2024/25 earnings by almost 10%. FY sales are likely to fall 7% with a 10% EBIT decline. We remain at Neutral on the stock with a new EUR

3h / 40m 3h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Tesco: P10 UK market share on the same trend as recent months

Tesco: "beat-and-raise" cycle still in motion post-H1

Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

Vicore Pharma: interesting play in the IPF space

Rémy Cointreau: we lower our FY24/25 EBIT as China confirms higher tariffs on cognac

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe